Jane Street
PRLD icon

Jane Street’s Prelude Therapeutics PRLD Stock Holding History

Jane Street’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$342K Buy
+64,100
New +$279K ﹤0.01% 8923

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Jane Street's PRLD Position: Q2 2026 in Review

Jane Street sold out of Prelude Therapeutics (PRLD) in Q2 2026, closing a stake of 192,963 shares — an estimated $840K sold.

Jane Street first reported a position in PRLD in Q3 2020 and held it in 12 quarters. The position peaked at $660K in Q1 2026. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Jane Street reported no remaining Prelude Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 192,963 Prelude Therapeutics shares in Q2 2026, an estimated $840K.
  • Jane Street first reported a position in Prelude Therapeutics in Q3 2020 and held it in 12 quarters.
  • Jane Street's Prelude Therapeutics position peaked at $660K in Q1 2026.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.